OakChart

Astrazeneca plc

AZNHealthcare·Drug Manufacturers - General·United Kingdom·Mega·NYSE·Nov 11 • 11:15 AM ET

184.44-2.32 (-1.24%)
2026-11-11 17:15 CET
Market cap
289,649.82 USD m
Revenue, TTM
62,384.00 USD m
Net income, TTM
11,030.00 USD m
Free cash flow, TTM
10,285.76 USD m
EPS diluted, TTM
7.07
P/E
26.10
Compare

Price

AZN against its 20, 50 and 200-day averages
2050200beatmiss
160.00170.00180.00190.008.2M16.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AZNclose 184.4420-day 177.1750-day 167.94200-day 180.20184.4452w low

13.3% under the 52-week high of 212.71 on 18 Feb 2026. 52-week low 153.41 on 3 Aug 2026. Last 15 sessions, 14.7% high to low

Profile

AZN
52-week range, 52% of the way up
153.41212.71

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Employees96100
IPOOct 17, 2003
Beta0.28
ATR, 14d4.52
Rel volume0.56
Short float0.20%
Insider own3.44%
Inst own61.47%

Snapshot

6 groups

Valuation

Index-
Market Cap286.05B
Enterprise Value312.16B
Income11.03B
Sales62.38B
Book/sh33.36
Cash/sh5.27
Dividend Est.3.34 (1.81%)
Dividend TTM3.23 (1.75%)
Dividend Ex-DateAug 07, 2026
Dividend Gr. 3/5Y1.78% 3.25%
Payout47.19%
Employees96100
IPOOct 17, 2003

Ratios

P/E26.10
Forward P/E16.23
PEG1.45
P/S4.59
P/B5.53
P/C35.03
P/FCF27.81
EV/EBITDA14.90
EV/Sales5.00
Quick Ratio0.79
Current Ratio1.01
Debt/Eq0.66
LT Debt/Eq0.56
Option/ShortYes / Yes

Earnings

EPS (ttm)7.07
EPS next Y11.36
EPS next Q2.33
EPS this Y12.04%
EPS next Y10.70%
EPS next 5Y11.21%
EPS past 3/5Y45.90% 22.05%
Sales past 3/5Y9.82% 16.31%
EPS Y/Y TTM17.34%
Sales Y/Y TTM7.32%
EPS Q/Q23.13%
Sales Q/Q6.70%
EarningsOct 30 BMO
EPS/Sales Surpr.7.91% 1.30%

Ownership

Insider Own3.44%
Insider Trans-0.02%
Inst Own61.47%
Inst Trans-1.12%
ROA9.41%
ROE22.60%
ROIC13.70%
Gross Margin74.11%
Oper. Margin23.31%
Profit Margin17.68%
SMA204.10%
SMA509.83%
SMA2002.35%
Trades-

Technical

Shs Outstand1.55B
Shs Float1.50B
Short Float0.20%
Short Ratio0.97
Short Interest3.03M
52W High212.71 -13.29%
52W Low153.41 20.22%
Volatility2.27% 2.07%
ATR (14)4.52
RSI (14)62.07
Beta0.28
Rel Volume0.56
Avg Volume3.14M
Volume532,826

Performance

Perf Week-2.42%
Perf Month18.37%
Perf Quarter17.30%
Perf Half Y-1.75%
Perf YTD5.09%
Perf Year5.27%
Perf 3Y48.40%
Perf 5Y45.32%
Perf 10Y238.73%
Recom1.55
Target Price228.71
Prev Close186.76
Price184.44
Change %-1.24%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Sep 15, 2026UpgradeDDeutsche BankSell → Hold
Sep 09, 2026InitiatedRRBC Capital MktsOutperform
Jul 13, 2026DowngradeHHSBC SecuritiesBuy → Hold

Peers

Mkt cap
TickerCompanyMkt cap
MRKMerck & Co Inc359.75B
NVSNovartis AG ADR292.06B
GSKGSK Plc ADR100.19B
PFEPfizer Inc166.58B
BMYBristol-Myers Squibb Co126.08B
JNJJohnson & Johnson668.99B
ABBVAbbvie Inc514.19B
LLYLilly(Eli) & Co1337.03B
SNYSanofi ADR114.11B
AMGNAMGEN Inc249.94B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Sharma ManiSee RemarksAug 08 '26Buy160.57203,24919,288Sep 11 04:05 PM
Sharma ManiSee RemarksMay 20 '26Sale185.7811,8932,209,48219,262May 22 04:05 PM

Held by

AUM
TickerCompanyAUM
PVALPutnam Focused Large Cap Value ETFAUM: 15.87B
AVDEAvantis International Equity ETFAUM: 19.73B
DIHPDimensional International High Profitability ETF-
PBPHPortfolio Building Block World Pharma and Biotech Index ETFAUM: 1.31B
DFICDimensional International Core Equity 2 ETF-
PPHVanEck Pharmaceutical ETFAUM: 1.09B
FVDFirst Trust Value Line Dividend Index FundAUM: 8.21B
DFAXDimensional World ex U.S. Core Equity 2 ETF-
IDEQLazard International Dynamic Equity ETFAUM: 2.12B
APIEActivePassive International Equity ETFAUM: 1.13B

News

latest 14 of 103
  • AstraZeneca acquires bacterial vaccine biotech, Omniose (Pharmaceutical Technology)
  • AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning (BioPharma Dive)
  • AstraZeneca's Reported $10 Billion Rhythm Bid Raises the Stakes for Palatin's Obesity Pipeline (NASDAQ: PTN) (FinanceWire)
  • AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US (Business Wire)
  • Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss (MarketWatch)
  • Loading…
  • RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report (Stocktwits)
  • Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report (Investing.com)
  • Novo hires new CFO as Wegovy pill hits more markets (CFO Dive)
  • AstraZeneca Beats On Accelerating Core EPS, But Reaffirmed Guidance And 2027 Headwinds Temper The Upside (Earnings Whispers)
  • Earnings roundup: AstraZenecas cost cuts, Alnylams slump and Regenerons resilience (BioPharma Dive)
  • AstraZeneca results reassure on long-term growth as three brokers raise price targets (Proactive)
  • FTSE 100 today: Stocks fall as crude slide drags oil majors lower (Investing.com)
  • SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus (Stocktwits)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-302.7902.5862.02016,20916,00116
2026Q22026-07-272.6302.4821.60715,38415,43416
2026Q12026-04-292.5802.5211.97315,28814,93317
2025Q42026-02-102.1202.0921.48815,50315,44513
2025Q32025-11-062.3802.2931.62315,19114,77914
2026Q4--2.329--16,60415
2027Q1--2.715--15,9772
2027Q2--2.665--16,3132
2027Q3--3.070--17,1732
2027Q4--2.680--17,6682

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY8.2108.2114.50154,07353,118
2025FY9.1609.1646.60058,73958,648
2026FY-10.263--62,678
2027FY-11.361--66,763
2028FY-12.598--70,815
2029FY-14.477--76,405
2030FY-16.065--81,473

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06152616,60416,14317,202
2026Q4S2026-11-04152616,60816,14317,202
2026Q4S2026-10-30151716,57616,14317,141
2026Q4S2026-10-25131216,65416,18517,178
2026Q4S2026-10-23141216,66016,18517,178
2026Q4S2026-10-22151216,66616,18517,178
2026Q4S2026-10-20131116,67516,18517,178
2026Q4S2026-10-16131016,69716,18517,178
2026Q4S2026-10-14131116,69516,18517,178
2026Q4S2026-10-13141116,70116,18517,178
2026Q4S2026-10-12141116,71116,18517,178
2026Q4S2026-10-09131116,68916,18517,178
2026Q4S2026-10-08131116,68216,18517,086
2026Q4S2026-10-07131116,68016,18517,086

Estimate history

EPS, annual2.371.7011.0262.4340.0792.1083.8124.5016.5467.0664
Period201720182019202020212022202320242025TTM
EPS, quarterly0.9150.961.8681.5721.6231.4881.9731.6071.998
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual22465220902438427594378334435145811540735873962384
Period201720182019202020212022202320242025TTM
Sales, quarterly135651489113588144571519115503152881538416209
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1266.2221267.0391312.1381312.6691549.4011549.81550.1631550.1041550.761550.76
Period201720182019202020212022202320242025MRQ
Shares, quarterly1550.2871550.1041550.1041550.1041550.2511550.761550.8331550.8331550.76
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue62,384.0058,739.0054,073.0045,811.0044,351.0037,833.0027,594.0024,384.0022,090.00
Cost of Goods Sold Incl. D&A16,150.0014,892.0013,528.0011,934.0016,249.0014,792.007,172.006,742.006,234.00
Gross Profit46,234.0043,847.0040,545.0033,877.0028,102.0023,041.0020,422.0017,642.0015,856.00
Selling, General and Administrative Excl. Other31,692.0029,840.0027,756.0024,466.0023,042.0020,130.0015,748.0014,839.0014,020.00
Research and Development14,501.0013,804.0012,218.0010,345.009,639.008,547.006,094.005,320.005,266.00
Other Operating Expense0.00-1.000.000.000.0047.00-11.00-4.000.00
Operating Income14,542.0014,008.0012,789.009,411.005,060.002,864.004,685.002,807.001,836.00
Interest Expense1,789.001,335.001,391.001,132.00889.00774.00736.00772.00741.00
Unusual Expense485.00882.003,144.002,033.002,125.003,827.00447.001,882.001,114.00
Net Income Before Taxes13,341.0012,409.008,719.006,911.002,506.00-201.003,943.001,664.002,106.00
Income Taxes2,266.002,169.001,650.00938.00-792.00-380.00772.00321.00-57.00
Consolidated Net Income11,034.0010,233.007,041.005,961.003,293.00115.003,144.001,227.002,050.00
Net Income From Continuing Operations11,030.0010,225.007,035.005,955.003,288.00112.003,196.001,335.002,155.00
Net Income11,030.0010,225.007,035.005,955.003,288.00112.003,196.001,335.002,155.00
EPS (Recurring)7.296.945.914.723.061.962.672.042.32
EPS (Basic, Before Extraordinaries)7.116.604.543.842.120.082.441.031.70
EPS (Diluted)7.076.554.503.812.110.082.431.031.70
EBITDA20,953.0019,498.0017,854.0014,345.0010,314.006,966.007,581.005,589.004,615.00
Non-Operating Income (Expense)1,073.00618.00465.00665.00460.001,536.00441.001,511.002,125.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense573.00539.25495.00434.25501.39498.15224.37209.79177.39
Price To Earnings Ratio26.2526.2562.5370.79205.95830.9682.09192.9689.23
Price To Sales Ratio4.084.933.794.614.754.434.765.384.29
Gross Margin74.1174.6574.9873.9563.3660.9074.0172.3571.78
Operating Margin23.3123.8523.6520.5411.417.5716.9811.518.31
Net Margin17.6817.4113.0113.007.410.3011.585.479.76
Shares Outstanding1,550.761,550.761,550.101,550.161,549.801,549.401,312.671,312.141,267.04
Market Capitalization289,649.82289,649.82406,307.87417,551.14420,232.54360,954.28262,479.49261,645.34192,453.78

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue16,209.0015,384.0015,288.0015,503.0015,191.0014,457.0013,588.0014,891.00
Cost of Goods Sold Incl. D&A4,115.004,069.003,655.004,311.003,966.003,589.003,200.004,806.00
Gross Profit12,094.0011,315.0011,633.0011,192.0011,225.0010,868.0010,388.0010,085.00
Selling, General and Administrative Excl. Other7,715.008,203.007,516.008,258.007,652.007,453.006,706.008,049.00
Research and Development3,647.003,662.003,462.003,730.003,551.003,455.003,089.003,571.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income4,379.003,112.004,117.002,934.003,573.003,415.003,682.002,036.00
Interest Expense477.00435.00393.00484.00434.00439.00349.00429.00
Unusual Expense268.00100.0060.0057.0079.00-21.00122.00100.00
Net Income Before Taxes3,977.002,809.003,926.002,629.003,234.003,137.003,409.001,671.00
Income Taxes842.00291.00833.00300.00709.00679.00481.00166.00
Consolidated Net Income3,116.002,508.003,081.002,329.002,535.002,448.002,921.001,500.00
Net Income From Continuing Operations3,117.002,507.003,080.002,326.002,533.002,450.002,916.001,500.00
Net Income3,117.002,507.003,080.002,326.002,533.002,450.002,916.001,500.00
EPS (Recurring)2.121.652.001.511.661.561.921.01
EPS (Basic, Before Extraordinaries)2.011.621.991.501.631.581.880.97
EPS (Diluted)2.001.611.971.491.621.571.870.96
EBITDA5,984.005,041.005,483.004,445.005,122.004,804.004,966.004,373.00
Non-Operating Income (Expense)343.00232.00262.00236.00174.00140.00198.00164.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense138.75141.00150.75142.50129.00137.25125.28129.75
Price To Earnings Ratio26.2528.2929.9160.5857.1655.7564.7662.53
Price To Sales Ratio4.084.765.004.944.043.834.123.79
Gross Margin74.6173.5576.0972.1973.8975.1776.4567.73
Operating Margin27.0220.2326.9318.9323.5223.6227.1013.67
Net Margin19.2316.3020.1515.0016.6716.9521.4610.07
Shares Outstanding1,550.761,550.831,550.831,550.761,550.251,550.101,550.101,550.10
Market Capitalization289,649.82294,074.07305,854.69570,072.64475,740.72433,440.48455,879.34406,307.87

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments5,741.005,654.005,962.006,405.006,398.007,992.006,218.005,680.004,582.00
Short Term Receivables14,301.0013,094.0011,935.009,923.008,795.005,651.005,181.005,708.005,267.00
Inventories6,557.005,288.005,424.004,699.008,983.004,024.003,193.002,890.003,035.00
Other Current Assets2,124.001,791.001,733.001,566.002,068.001,877.00971.001,240.00-
Total Current Assets28,723.0025,827.0025,054.0022,593.0026,244.0019,544.0015,563.0015,518.0012,884.00
Net Property, Plant & Equipment14,703.0011,647.0010,502.009,449.0010,171.008,917.008,335.007,421.007,615.00
Total Investments and Advances3,023.002,082.001,905.001,216.001,339.001,318.001,520.001,079.001,540.00
Long-Term Note Receivable662.00475.00437.00502.00504.00325.00348.00328.00755.00
Intangible Assets59,088.0058,202.0058,137.0059,127.0062,384.0032,792.0032,501.0033,666.0038,013.00
Deferred Tax Assets5,819.005,347.004,718.003,263.004,330.003,438.002,718.002,379.002,189.00
Other Assets2,056.00455.00366.00333.00391.00395.00392.00260.00358.00
Total Assets114,074.00104,035.00101,119.0096,483.00105,363.0066,729.0061,377.0060,651.0063,354.00
Short Term Debt Incl. Current Port. of LT Debt3,486.002,676.005,400.005,542.001,893.002,386.002,010.001,754.002,247.00
Accounts Payable3,820.003,640.003,267.002,550.002,824.002,350.001,774.001,720.003,611.00
Income Tax Payable1,084.001,406.001,584.00896.00916.001,127.001,361.001,164.001,350.00
Other Current Liabilities22,227.0020,144.0020,291.0017,305.0016,961.0014,444.0012,972.0011,654.009,175.00
Total Current Liabilities30,617.0027,866.0030,542.0026,293.0022,594.0020,307.0018,117.0016,292.0016,383.00
Long Term Debt26,136.0027,619.0023,222.0023,690.0028,888.0017,994.0016,217.0017,359.0015,560.00
Provision for Risks Charges2,023.002,251.002,647.002,064.003,410.003,786.003,648.002,896.002,930.00
Deferred Tax Liabilities3,500.003,305.002,844.002,944.006,206.002,918.002,490.003,286.003,995.00
Other Liabilities3,024.002,123.002,698.004,434.004,978.006,086.006,309.006,774.007,844.00
Total Liabilities65,300.0063,164.0061,953.0059,425.0066,076.0051,091.0046,781.0046,607.0046,712.00
Non-Equity Reserves55.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity48,667.0040,786.0039,143.0037,037.0039,268.0015,622.0013,127.0012,468.0014,960.00
Total Shareholders Equity48,667.0040,786.0039,143.0037,037.0039,268.0015,622.0013,127.0012,468.0014,960.00
Accumulated Minority Interest52.0085.0023.0021.0019.0016.001,469.001,576.001,682.00
Total Equity48,719.0040,871.0039,166.0037,058.0039,287.0015,638.0014,596.0014,044.0016,642.00
Total Liabilities & Stockholders Equity114,074.00104,035.00101,119.0096,483.00105,363.0066,729.0061,377.0060,651.0063,354.00
Book Value Per Share31.3826.3125.2523.9025.3411.9010.009.8411.81
Tangible Book Value Per Share-6.72-11.24-12.25-14.25-14.92-13.08-14.77-16.73-18.21
Full-Time Employees96,10094,30089,90083,50083,10076,10070,60064,40061,100
Price to Book Ratio5.609.9811.2311.959.1916.8019.9415.4412.80
Return on Assets9.386.866.033.260.134.992.193.484.77
Return on Equity22.8617.6015.638.620.4122.2310.4315.7120.13
Return on Invested Capital13.6710.289.555.410.169.514.557.229.83
Quick Ratio0.720.740.640.680.760.760.680.780.60
Current Ratio0.940.930.820.861.160.960.860.950.79

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income13,147.7212,402.008,691.006,899.002,501.00-265.003,916.001,548.001,993.00
Depreciation6,103.235,490.005,065.004,934.005,254.004,102.002,896.002,782.002,779.00
Other Funds (Non Cash)-3,023.83-1,894.00-659.00-1,501.00-1,644.00139.00-2,327.00-891.00-1,322.00
Funds from Operations16,227.1215,998.0013,097.0010,332.006,111.003,976.004,485.003,439.003,450.00
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2,941.95-1,137.00-893.00300.003,757.002,021.00361.00-346.00-639.00
Cash from Operating Activities13,285.1814,861.0012,204.0010,632.009,868.005,997.004,846.003,093.002,811.00
Capital Expenditures-7,062.94-5,905.00-4,586.00-3,778.00-2,571.00-2,200.00-2,606.00-2,460.00-1,371.00
Net Assets From Acquisitions-1,318.62-1,413.00-3,782.00-1,099.00-820.00-10,055.00-822.00-709.00-349.00
Sale of Fixed Assets and Businesses15.8513.0055.00132.00282.0013.00106.0037.0012.00
Purchase or Sale of Investments-225.04-108.00-133.00-87.00-143.00605.001,999.00125.00140.00
Purchase of Investments-235.00-239.00-254.00-216.00-185.00-276.00-127.00-87.00-289.00
Sale Or Maturity of Investments9.96131.00121.00129.0042.00881.002,126.00212.00429.00
Other Uses0.000.000.000.00-215.00-211.000.000.000.00
Other Sources218.59136.00123.00481.00447.00607.00991.002,226.002,338.00
Cash from Investing Activities-8,372.17-7,277.00-8,323.00-4,351.00-3,020.00-11,241.00-332.00-781.00770.00
Cash Dividends Paid-4,862.69-4,965.00-4,629.00-4,481.00-4,364.00-3,856.00-3,572.00-3,592.00-3,484.00
Change in Capital Stock-723.92-481.00-43.0033.0029.0029.0030.003,525.0034.00
Repurchase of Common Pref Stock-766.83-521.00-81.000.000.000.000.000.000.00
Sale of Common Pref Stock42.9040.0038.0033.0029.0029.0030.003,525.0034.00
Proceedsfrom Stock Options42.9040.0038.0033.0029.0029.0030.003,525.0034.00
Issuance or Reduction of Debt, Net397.85-1,650.001,809.00-965.00-1,197.007,894.001,647.00-1,516.001,473.00
Change in Long Term Debt0.000.000.000.000.000.00-0.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00--0.00
Reduction of Long Term Debt0.000.000.000.000.000.00-0.000.00
Net Financing Active Other Cash Flow-59.98107.00-817.00-886.00-1,047.00-29.00-101.004.00-67.00
Other Financing Activities Uses-58.02-6.00-833.00-886.00-1,047.00-29.00-101.000.00-67.00
Cash from Financing Activities-5,132.39-7,361.00-3,996.00-6,567.00-6,823.003,798.00-2,203.00-1,765.00-2,044.00
Exchange Rate Effect-12.6846.00-93.00-60.00-80.00-62.0012.005.00-38.00
Net Change in Cash-232.06269.00-208.00-346.00-55.00-1,508.002,323.00552.001,499.00
Free Cash Flow10,285.7612,051.0010,280.009,271.008,777.004,906.003,885.002,114.001,768.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow46.9340.8936.2644.0647.70159.74419.97--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments8,166.004,968.007,675.005,741.008,182.007,108.00
Short Term Receivables16,379.0015,989.0015,165.0014,301.0015,153.0015,169.00
Inventories6,883.006,932.006,570.006,557.006,593.006,467.00
Other Current Assets20.0076.00203.002,124.0012.00195.00
Total Current Assets31,448.0027,965.0029,613.0028,723.0029,940.0028,939.00
Net Property, Plant & Equipment16,778.0016,300.0014,941.0014,703.0013,783.0013,229.00
Total Investments and Advances3,250.003,310.003,047.003,023.002,788.002,648.00
Intangible Assets59,303.0058,904.0058,102.0059,088.0059,410.0059,147.00
Deferred Tax Assets6,655.006,487.005,593.005,819.006,129.006,256.00
Other Assets1,062.001,516.001,533.002,056.001,247.000.00
Total Assets119,922.00115,833.00114,015.00114,074.00114,456.00112,422.00
Short Term Debt Incl. Current Port. of LT Debt5,394.006,234.007,959.003,486.006,553.006,853.00
Accounts Payable23,572.0022,893.0022,505.0025,280.0025,028.0023,986.00
Income Tax Payable1,621.001,468.001,299.001,084.001,268.001,429.00
Other Current Liabilities680.00958.00807.00767.001,205.001,268.00
Total Current Liabilities31,267.0031,553.0032,570.0030,617.0034,054.0033,536.00
Long Term Debt28,797.0026,005.0025,959.0026,136.0026,079.0025,986.00
Provision for Risks Charges1,768.001,819.001,857.002,023.002,200.002,390.00
Deferred Tax Liabilities3,617.003,463.003,471.003,500.003,604.003,615.00
Other Liabilities2,659.002,623.002,774.003,024.002,548.002,085.00
Total Liabilities68,108.0065,463.0066,631.0065,300.0068,485.0067,612.00
Non-Equity Reserves0.000.000.0055.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity51,728.0050,295.0047,333.0048,667.0045,888.0044,719.00
Total Shareholders Equity51,728.0050,295.0047,333.0048,667.0045,888.0044,719.00
Accumulated Minority Interest86.0075.0051.0052.0083.0091.00
Total Equity51,814.0050,370.0047,384.0048,719.0045,971.0044,810.00
Total Liabilities & Stockholders Equity119,922.00115,833.00114,015.00114,074.00114,456.00112,422.00
Book Value Per Share33.3632.4330.5231.3829.6028.85
Tangible Book Value Per Share-4.88-5.55-6.94-6.72-8.72-9.31
Full-Time Employees---96,100--
Price to Book Ratio5.606.216.2812.4210.6410.56
Return on Assets9.419.159.439.388.577.65
Return on Equity22.6021.9923.5122.8621.7019.70
Return on Invested Capital3.873.294.203.113.523.47
Quick Ratio0.790.670.710.720.690.67
Current Ratio1.010.890.910.940.880.86

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income3,965.762,784.463,914.002,483.503,309.533,319.91
Depreciation1,609.021,921.861,366.001,206.351,581.671,467.98
Other Funds (Non Cash)-553.05-1,361.19-854.00-255.59-416.08-759.57
Funds from Operations5,021.743,345.134,426.003,434.264,475.114,028.31
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-294.02-434.88-1,000.00-1,213.05859.47-367.78
Cash from Operating Activities4,727.722,910.243,426.002,221.215,334.593,660.53
Capital Expenditures-1,211.34-3,094.94-1,538.00-1,218.66-1,762.67-2,008.45
Net Assets From Acquisitions-600.06-32.37-257.00-429.19-347.03-287.64
Sale of Fixed Assets and Businesses1.023.978.002.85-0.039.30
Purchase or Sale of Investments-151.0243.16-117.00-0.18-33.65-76.16
Purchase of Investments-151.0240.17-117.00-7.15-40.47-193.55
Sale Or Maturity of Investments0.002.990.006.976.83117.40
Other Uses0.000.000.000.000.000.00
Other Sources15.24119.6445.0038.700.7388.81
Cash from Investing Activities-1,946.16-2,960.54-1,859.00-1,606.47-2,142.65-2,274.15
Cash Dividends Paid-1,670.976.12-3,287.0089.16-1,643.19-109.19
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-101.92-38.61-602.0018.60-12.89-13.09
Repurchase of Common Pref Stock-105.94-44.57-612.00-4.31-17.99-17.45
Sale of Common Pref Stock4.025.9710.0022.915.094.35
Proceedsfrom Stock Options4.025.9710.0022.915.094.35
Issuance or Reduction of Debt, Net2,108.51-2,467.034,322.00-3,072.28-370.77683.03
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow19.880.16-72.00-8.018.923.07
Other Financing Activities Uses19.880.16-72.00-6.050.000.00
Cash from Financing Activities255.28-2,586.96267.00-3,067.70-2,108.71455.38
Exchange Rate Effect-7.019.02-18.003.31-12.4830.60
Net Change in Cash3,029.83-2,628.241,816.00-2,449.651,070.741,872.36
Free Cash Flow4,050.142,150.082,879.001,206.544,633.822,969.38
Price to Free Cash Flow46.9348.3844.8840.5429.1332.72

Revenue breakdown

Pharmaceutical Preparations2024: 54.07B 2025: 58.74B
Australia2024: 439.00M 2025: 454.00M
Canada2024: 937.00M 2025: 954.00M
China2024: 6.42B 2025: 6.64B
France2024: 1.28B 2025: 1.41B
Germany2024: 2.52B 2025: 2.89B
Italy2024: 949.00M 2025: 1.08B
Japan2024: 3.45B 2025: 3.56B
Other Americas excluding US and Canada2024: 2.25B 2025: 2.63B
Other Asia, Africa and Australasia excluding Australia, China and Japan2024: 2.33B 2025: 2.72B
Other, Europe2024: 3.66B 2025: 4.32B
Spain2024: 994.00M 2025: 1.14B
Sweden2024: 2.29B 2025: 2.62B
United Kingdom2024: 4.74B 2025: 4.36B
United States2024: 21.81B 2025: 23.97B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.20%3.0M1497.6M3.44M
2026-10-150.22%3.3M1497.6M3.33M
2026-09-300.17%2.6M1497.6M3.38M
2026-09-150.14%2.1M1497.6M3.26M
2026-08-310.19%2.9M1497.7M3.08M
2026-08-140.13%1.9M1497.7M2.83M
2026-07-310.12%1.8M1497.5M2.25M
2026-07-150.17%2.5M1497.5M2.19M
2026-06-300.10%1.5M1497.5M1.99M
2026-06-150.09%1.3M1497.4M1.95M
2026-05-290.12%1.7M1475.8M1.93M
2026-05-150.15%2.2M1476.1M1.96M
2026-04-300.12%1.8M1476.1M2.16M
2026-04-150.12%1.7M1476.2M1.80M
2026-03-310.11%1.6M1476.2M1.49M
2026-03-130.13%2.0M1476.2M1.14M
2026-02-270.16%2.4M1476.2M837.11K
2026-02-130.17%2.5M1475.9M531.60K
2026-01-300.26%3.9M1475.9M1.77K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call11073.3075.700.002.1640.000.000.990-0.0640.007
call11568.3070.600.001.9820.000.000.989-0.0640.008
call12063.3065.500.001.7970.000.000.988-0.0630.009
call12558.3060.500.001.6540.000.000.987-0.0630.009
call13053.3055.6055.581.5451.000.000.986-0.0630.010
call13548.2050.900.001.4860.000.000.985-0.0620.011
call14043.3045.6021.701.2751.000.000.983-0.0610.012
call14538.4040.9041.611.2084.000.000.981-0.0610.013
call15033.4035.4037.700.96633.000.000.979-0.0600.014
call15528.4030.4029.500.84567.000.000.976-0.0580.016
call16023.3025.5026.670.7453300.000.972-0.0570.018
call16518.4020.2022.000.5738610.000.967-0.0550.021
call17013.7015.6016.800.5202,4530.000.912-0.1090.046
call1759.0010.6012.070.3911,5920.000.848-0.1340.068
call1805.106.109.200.3041,8140.000.708-0.1670.099
call1852.352.702.600.2587171.000.478-0.1780.115
call1900.801.101.000.2677121.000.262-0.1540.094
call1950.300.500.750.2972430.000.135-0.1120.063
call2000.050.350.080.3555471.000.087-0.0960.046
call2100.000.200.050.4611660.000.038-0.0620.024
call2200.000.250.300.58763.000.000.031-0.0660.020
call2300.000.200.080.7052.000.000.027-0.0700.018
call2400.000.200.050.8164.000.000.024-0.0730.016
put1100.000.200.081.4764.000.00-0.010-0.0610.007
put1150.000.200.111.3595.000.00-0.010-0.0600.008
put1200.000.200.151.2451.000.00-0.011-0.0590.009
put1250.000.200.081.14523.000.00-0.012-0.0580.009
put1300.000.200.051.03524.000.00-0.014-0.0570.010
put1350.000.200.100.94227.000.00-0.015-0.0560.011
put1400.000.200.180.84584.000.00-0.016-0.0550.012
put1450.000.250.880.7493890.00-0.018-0.0540.013
put1500.000.200.050.65955015.00-0.021-0.0520.014
put1550.000.250.050.5676291.00-0.024-0.0500.016
put1600.000.250.120.4741,1490.00-0.028-0.0480.018
put1650.000.150.150.3837371.00-0.034-0.0450.022
put1700.000.400.100.3755730.00-0.087-0.0980.046
put1750.350.650.350.3127180.00-0.152-0.1230.068
put1801.201.501.400.2891442.00-0.292-0.1580.100
put1853.203.603.300.2925762.00-0.521-0.1690.115
put1906.507.305.400.3301070.00-0.737-0.1420.094
put19510.2011.705.600.38561.000.00-0.864-0.0990.063
put20015.0017.300.000.5700.000.00-0.913-0.0820.046
put21024.6026.800.000.6930.000.00-0.961-0.0480.024
put22035.1036.800.000.8600.000.00-0.968-0.0510.020
put23044.6046.900.001.0240.000.00-0.973-0.0540.018
put24054.5056.800.001.1550.000.00-0.976-0.0550.016

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-10-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-30SEC
2026-10-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-27SEC
2026-10-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-22SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-05SEC
2026-10-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-02SEC
2026-10-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-01SEC
2026-10-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-01SEC
2026-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-29SEC
2026-09-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-23SEC
2026-09-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-21SEC
2026-09-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-21SEC
2026-09-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-18SEC
2026-09-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-15SEC
2026-09-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-15SEC
2026-09-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-14SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-08-08SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-08-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-083.25K100
2026-070000
2026-060000
2026-05002.21M1
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
NORGES BANK2.18%
Jupiter Topco LLC0.77%
LBP AM SA0.34%
DIMENSIONAL FUND ADVISORS LP0.19%
Evelyn Partners Group Ltd0.14%
AEGON ASSET MANAGEMENT UK PLC0.12%
Connor, Clark & Lunn Investment Management Ltd.0.11%
Liontrust Investment Partners LLP0.10%
CAISSE DE DEPOT ET PLACEMENT DU QUEBEC0.09%
WCM INVESTMENT MANAGEMENT, LLC0.08%

Funds

Fund% owned
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND1.42%
iShares iBoxx $ Investment Grade Corporate Bond ETF1.32%
VANGUARD TOTAL INTERNATIONAL BOND II INDEX FUND1.13%
VANGUARD TOTAL INTERNATIONAL BOND INDEX FUND1.06%
VANGUARD WELLINGTON FUND0.98%
VANGUARD DEVELOPED MARKETS INDEX FUND0.95%
VANGUARD LONG-TERM CORPORATE BOND INDEX FUND0.92%
VANGUARD LONG-TERM INVESTMENT-GRADE FUND0.77%
VANGUARD PRIMECAP FUND0.77%
iShares Core MSCI EAFE ETF0.72%

OakChart. AZN. Cached 15 minutes.